Table 3.

Association between intake of at least one systemic antiherpetic drugs and incidence of dementia - Cox models. ‶Echantillon Généraliste des Bénéficiaires.″ 2009–2017

	Adjusted modela
	Events	aHR	95% CI	P-value
In all the subjects (n= 68291)
All dementias	8883	0.90	0.82–0.99	0.03
Alzheimer’s disease	5366	0.85	0.75–0.96	0.009
Vascular dementia	1784	0.80	0.65–0.995	0.045
After exclusion of immunocompromised subjects, subjects with cancer or with an hospitalization related to herpesviruses (n=52254)
All dementias	7044	0.84	0.75–0.94	0.002
Alzheimer’s disease	4260	0.82	0.71–0.95	0.007
Vascular dementia	1433	0.77	0.60–0.99	0.04
After carrying out a lag-time of 1 year (n= 68291)
All dementias	8883	0.86	0.78–0.95	0.004
Alzheimer’s disease	5366	0.78	0.68–0.90	0.001
Vascular dementia	1784	0.87	0.69–1.09	0.23
After exclusion of participants with ≥ 2 deliveries of systemic AHDs per year of follow-up (n= 67904)
All dementias	8856	0.91	0.83–0.997	0.04
Alzheimer’s disease	5351	0.85	0.75–0.97	0.01
Vascular dementia	1781	0.83	0.66–1.03	0.09

Abbreviations: aHR adjusted hazard ratios, 95% CI 95% confidence interval, AHD antiherpetic drug

^aAdjustment for age at inclusion, sex, being beneficiary of a complementary health insurance for low-income people at inclusion, hypertension, diabetes, hypercholesterolemia, heart disease, stroke, intake of nonsteroidal anti-inflammatory drugs, systemic, or inhaled glucocorticoids the year before inclusion, number of different medications the year before inclusion, number of outpatient medical consultations the year before inclusion